Literature DB >> 34705128

Paradoxical manifestations during tuberculous meningitis treatment among HIV-negative patients: a retrospective descriptive study and literature review.

Rogelio Domínguez-Moreno1, Miguel García-Grimshaw2, David Medina-Julio3, Carlos Cantú-Brito3, Alejandra González-Duarte3.   

Abstract

BACKGROUND: Tuberculous meningitis (TBM) is the most frequent, severe, and disabling form of central nervous system (CNS) tuberculosis (TB). TBM paradoxical manifestations are characterized by clinical or paraclinical worsening after 1 month of effective anti-TB treatment in patients who initially responded to treatment despite the use of adjunctive corticosteroids.
METHODS: Retrospective descriptive study of consecutive HIV-negative adult patients (≥ 18 years) with definitive TBM who developed a paradoxical manifestation following anti-TB in a tertiary-care hospital in Mexico from 2009 to 2019; we also conducted a literature review of published cases/series of paradoxical manifestations in HIV-negative patients from 1980 to 2020.
RESULTS: We detected 84 cases of definitive TBM; 55 (68.7%) HIV-negative patients and 29 (36.3%) HIV-infected patients. Among HIV-negative patients, four (7.3%), three female and one male (19-49 years old), developed a paradoxical manifestation within 4-14 weeks following treatment initiation despite receiving adequate corticosteroid doses; Mycobacterium bovis was isolated from the cerebrospinal fluid of three cases and Mycobacterium tuberculosis in one more. Two patients developed vasculopathy-related cerebral infarctions, one severe basilar meningitis, and hydrocephalus, one more a tuberculoma. Two were treated with intravenous cyclophosphamide, and two with steroids. One of the patients treated with steroids died; patients who received cyclophosphamide had a good clinical response.
CONCLUSIONS: This case series illustrates the diverse clinical/radiologic paradoxical manifestations of TBM in HIV-negative patients. Cyclophosphamide may be safe and effective in treating TBM-associated paradoxical manifestations. Specific diagnostic and care protocols for these patients are needed.
© 2021. Fondazione Società Italiana di Neurologia.

Entities:  

Keywords:  Central nervous system tuberculosis; Cyclophosphamide; Mycobacterial infection; Paradoxical manifestation; Tuberculous meningitis

Mesh:

Substances:

Year:  2021        PMID: 34705128     DOI: 10.1007/s10072-021-05693-2

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.830


  62 in total

Review 1.  Paradoxical reaction in HIV negative tuberculous meningitis.

Authors:  Ravindra Kumar Garg; Hardeep Singh Malhotra; Neeraj Kumar
Journal:  J Neurol Sci       Date:  2014-03-19       Impact factor: 3.181

2.  Paradoxical reaction in HIV-negative tuberculous meningitis patients with spinal involvement.

Authors:  Yin Liu; Zheng Wang; Guang Yao; Yuying Lu; Zhongyang Hu; Huan Yao; Qinghua Zhang; Haixia Zhu; Zhi Song; Wei Wang; Ding Liu
Journal:  Int J Infect Dis       Date:  2018-12-04       Impact factor: 3.623

3.  Treatment-Associated Inflammatory Deterioration in Tuberculous Meningitis: Unpicking the Paradox.

Authors:  Nguyen Thuy Thuong Thuong; Guy E Thwaites
Journal:  J Infect Dis       Date:  2017-03-01       Impact factor: 5.226

4.  Clinical features, outcomes and prognostic factors of tuberculous meningitis in adults worldwide: systematic review and meta-analysis.

Authors:  Lan Wen; Maolin Li; Tao Xu; Xinyuan Yu; Lijun Wang; Kunyi Li
Journal:  J Neurol       Date:  2019-09-04       Impact factor: 4.849

5.  Intracranial tuberculomas in patients with tuberculous meningitis: predictors and prognostic significance.

Authors:  H K Anuradha; R K Garg; M K Sinha; A Agarwal; R Verma; M K Singh; R Shukla
Journal:  Int J Tuberc Lung Dis       Date:  2011-02       Impact factor: 2.373

6.  Paradoxical reaction in tuberculous meningitis: presentation, predictors and impact on prognosis.

Authors:  Anurag Kumar Singh; Hardeep Singh Malhotra; Ravindra Kumar Garg; Amita Jain; Neeraj Kumar; Neera Kohli; Rajesh Verma; Praveen Kumar Sharma
Journal:  BMC Infect Dis       Date:  2016-06-21       Impact factor: 3.090

Review 7.  Tuberculous meningitis.

Authors:  Robert J Wilkinson; Ursula Rohlwink; Usha Kant Misra; Reinout van Crevel; Nguyen Thi Hoang Mai; Kelly E Dooley; Maxine Caws; Anthony Figaji; Rada Savic; Regan Solomons; Guy E Thwaites
Journal:  Nat Rev Neurol       Date:  2017-09-08       Impact factor: 42.937

Review 8.  Tuberculous Meningitis: Pathogenesis, Immune Responses, Diagnostic Challenges, and the Potential of Biomarker-Based Approaches.

Authors:  Charles M Manyelo; Regan S Solomons; Gerhard Walzl; Novel N Chegou
Journal:  J Clin Microbiol       Date:  2021-02-18       Impact factor: 5.948

9.  Prognostic Models for 9-Month Mortality in Tuberculous Meningitis.

Authors:  Le Thi Phuong Thao; A Dorothee Heemskerk; Ronald B Geskus; Nguyen Thi Hoang Mai; Dang Thi Minh Ha; Tran Thi Hong Chau; Nguyen Hoan Phu; Nguyen Van Vinh Chau; Maxine Caws; Nguyen Huu Lan; Do Dang Anh Thu; Nguyen Thuy Thuong Thuong; Jeremy Day; Jeremy J Farrar; M Estee Torok; Nguyen Duc Bang; Guy E Thwaites; Marcel Wolbers
Journal:  Clin Infect Dis       Date:  2018-02-01       Impact factor: 9.079

10.  Clinical, Imaging, and Laboratory Characteristics of Adult Mexican Patients with Tuberculous Meningitis: A Retrospective Cohort Study.

Authors:  Miguel García-Grimshaw; Francisco Alejandro Gutiérrez-Manjarrez; Samuel Navarro-Álvarez; Alejandra González-Duarte
Journal:  J Epidemiol Glob Health       Date:  2020-03
View more
  2 in total

1.  Paroxysmal sympathetic hyperactivity syndrome in tuberculous meningitis with paradoxical reaction.

Authors:  Andre Marolop Pangihutan Siahaan; Steven Tandean; Rr Suzy Indharty; Bahagia Willibrodus Maria Nainggolan; Martin Susanto
Journal:  Int J Surg Case Rep       Date:  2022-09-08

2.  Magnetic Resonance Imaging Findings of Intraspinal Tuberculoma in Children.

Authors:  Yirui Zhou; Yong Qin; Tong Mu; Helin Zheng; Jinhua Cai
Journal:  Front Neurol       Date:  2022-08-02       Impact factor: 4.086

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.